Trumenba FDA Approval History
FDA Approved: Yes (First approved October 29, 2014)
Brand name: Trumenba
Generic name: meningococcal group B vaccine
Company: Pfizer Inc.
Treatment for: Meningococcal Meningitis Prophylaxis
Trumenba (meningococcal group B vaccine) is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in adolescents and young adults.
Development timeline for Trumenba
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.